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Synthesis, isomerisation and biological properties
of mononuclear ruthenium complexes containing
the bis[4(4’-methyl-2,2’-bipyridyl)]-1,7-heptane
ligand†
Biyun Sun,a Hannah M. Southam,b Jonathan A. Butler,‡b Robert K. Poole,b
Alexandre Burgun,c Andrew Tarzia,c F. Richard Keene *c,d and J. Grant Collins *a
A series of mononuclear ruthenium(II) complexes containing the tetradentate ligand bis[4(4’-methyl-2,2’-
bipyridyl)]-1,7-heptane have been synthesised and their biological properties examined. In the synthesis
of the [Ru(phen’)(bb7)]
2+ complexes (where phen’ = 1,10-phenanthroline and its 5-nitro-, 4,7-dimethyl-
and 3,4,7,8-tetramethyl- derivatives), both the symmetric cis-α and non-symmetric cis-β isomers
were formed. However, upon standing for a number of days (or more quickly under harsh conditions) the
cis-β isomer converted to the more thermodynamically stable cis-α isomer. The minimum inhibitory con-
centrations (MIC) and the minimum bactericidal concentrations (MBC) of the ruthenium(II) complexes
were determined against six strains of bacteria: Gram-positive Staphylococcus aureus (S. aureus) and
methicillin-resistant S. aureus (MRSA); and the Gram-negative Escherichia coli (E. coli) strains MG1655,
APEC, UPEC and Pseudomonas aeruginosa (P. aeruginosa). The results showed that the [Ru(5-NO2phen)-
(bb7)]
2+ complex had little or no activity against any of the bacterial strains. By contrast, for the other cis-
α-[Ru(phen’)(bb7)]2+ complexes, the antimicrobial activity increased with the degree of methylation. In
particular, the cis-α-[Ru(Me4phen)(bb7)]2+ complex showed excellent and uniform MIC activity against all
bacteria. By contrast, the MBC values for the cis-α-[Ru(Me4phen)(bb7)]2+ complex varied considerably
across the bacteria and even within S. aureus and E. coli strains. In order to gain an understanding of the
relative antimicrobial activities, the DNA-binding affinity, cellular accumulation and water–octanol par-
tition coefficients (log P) of the ruthenium complexes were determined. Interestingly, all the [Ru(phen’)-
(bb7)]
2+ complexes exhibited stronger DNA binding affinity (Ka ≈ 1 × 107 M−1) than the well-known DNA-
intercalating complex [Ru(phen)2(dppz)]
2+ (where dppz = dipyrido[3,2-a:2’,3’-c]phenazine).
Introduction
Due to a developing resistance to antimicrobial drugs, bac-
terial diseases are becoming a significantly greater threat to
humans. Of note, the World Health Organisation has stated
that antimicrobial resistance is one of the most important pro-
blems currently affecting global health, food security and
development.1 As a consequence, there is considerable interest
in the development of new classes of antimicrobial agents,
and while the development of new drugs based upon organic
compounds continues, transition metal-based antimicrobial
agents in general have been attracting attention – and ruthe-
nium(II) complexes in particular.2–14 A range of ruthenium(II)
complexes have been studied, and generally have shown good
activity against Gram-positive bacteria, but variable and often
poor activity against Gram-negative species.10–12
Dwyer and co-workers were the first to study the biological
activity of mononuclear tris(bidentate) inert metal complexes
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with ligands such as 1,10-phenanthroline (phen) and its
derivatives {e.g. 3,4,7,8-tetramethyl-1,10-phenanthroline
(Me4phen) and 5-nitro-1,10-phenanthroline (5-NO2phen)}.
9
More recently, a wide range of mononuclear {e.g. [Ru(2,9-
Me2phen)2(dppz)]
2+} (2,9-Me2phen = 2,9-dimethyl-1,10-phen-
anthroline; dppz = dipyrido[3,2-a:2′,3′-c]phenazine)10 and di-
and oligo-nuclear polypyridylruthenium(II)12,14,15 complexes
have been examined. In particular, earlier studies from our lab-
oratories have examined the antimicrobial properties of di-, tri-
and tetra-nuclear polypyridylruthenium(II) complexes in which
the metal centres are linked by the bis[4(4′-methyl-2,2′-bipyri-
dyl)]-1,n-alkane ligand (“bbn”; see Fig. 1).
14 While these oligo-
nuclear ruthenium complexes showed excellent activity against
drug-sensitive Gram-positive bacterial strains, and maintained
the activity against drug-resistant strains, they exhibited rela-
tively poor activity against some Gram-negative strains.16 More
recently, we synthesised mononuclear ruthenium complexes
that contained the bbn moiety (for n = 10 and 12), but as a tetra-
dentate ligand,17 rather than as a ligand linking metal centres.
While the cis-α-[Ru(phen)(bb12)]2+ species showed better activity
towards the clinically-important Gram-negative Pseudomonas
aeruginosa, its activity against other bacteria was only equivalent
to [Ru(Me4phen)3]
2+,8 the most active of the ruthenium com-
plexes prepared by Dwyer and co-workers sixty years ago. The
cis-α-[Ru(phen)(bb10)]2+ complex was less active than cis-α-[Ru-
(phen)(bb12)]
2+ and [Ru(Me4phen)3]
2+ against most of the
bacterial strains.17 The antimicrobial activity of the [Ru(phen)-
(bbn)]
2+ complexes could be potentially improved through an
increase of the lipophilicity, for example by utilising the bb16
ligand. However, an alternative approach is to decrease the lipo-
philicity of the bbn chain but increase the electron density at
the ruthenium centre through the incorporation of electron-
donating groups on the 1,10-phenanthroline ligand. It has been
established that the antimicrobial activity of the metal com-
plexes is significantly affected by the cellular uptake,15 which in
turn is presumably sensitive to the charge on the metal centre
as well as the overall lipophilicity. Consequently, the modu-
lation of the electron density at the metal centre could provide
higher uptake and greater ability to modulate the differential
uptake between bacterial and eukaryotic cells.
Herein, we describe the synthesis of a series of
complexes involving 1,10-phenanthroline and some of its deriva-
Fig. 1 The bbn ligand and the Rubbn, Rubbn-tri and Rubbn-tetra complexes.
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tives – [Ru(phen′)(bb7)]
2+ {where phen′ = phen; 4,7-dimethyl-
1,10-phenanthroline (Me2phen); Me4phen; and 5-NO2phen} –
and an examination of their DNA binding, cellular uptake and
antimicrobial activity against a range of bacteria. Synthetically,
the results indicate that although the cis-β-[Ru(phen′)(bb7)]2+
complexes are formed initially they are unstable and are con-
verted to the cis-α isomer and, to a very small extent, the corres-
ponding [Ru(phen′)(Me2bpy)2]
2+ species. The cis-α-[Ru(Me4phen)
(bb7)]
2+ complex showed uniformly high activity against Gram-
positive and Gram-negative bacteria. Furthermore, the results
demonstrate the effect of the electron density at the ruthenium
centre on the cellular uptake of the metal complexes.
Results
Synthesis of cis-α-[Ru(phen′)(bb7)]2+ complexes
The synthesis of the cis-α and cis-β isomers of [Ru(phen)-
(bb12)]
2+ was carried out as previously reported.17
The synthesis of a series of mononuclear cis-α-[Ru(phen′)-
(bb7)]
2+ complexes was achieved with good yields, as shown in
Scheme 1, by heating cis,cis-[RuCl2(DMSO)2(phen′)]
17 to
130–140 °C with the bb7 ligand in ethylene glycol: the 2+ com-
plexes were isolated from higher-charged species using cation-
exchange chromatography on a SP Sephadex C-25 column with
aqueous sodium chloride as the eluent, and the resulting solid
products recrystallised from acetonitrile/diethyl ether.
Subsequent cation-exchange chromatography on a SP Sephadex
C-25 column (1 metre) with sodium toluene-4-sulfonate as the
eluent realised two bands – the cis-α isomer and corresponding
[Ru(phen′)(Me2bpy)2]
2+ species as a minor product. All the com-
plexes were characterised by microanalysis, NMR spectroscopy
and high-resolution electrospray ionisation (ESI) mass spec-
trometry. The cis-α-[Ru(Me4phen)(bb7)]2+ complex was also
characterised by X-ray crystallography (see Table 1 and Fig. 2).
In our recent synthetic study17 of the analogous [Ru(phen)-
(bb10)]
2+ and [Ru(phen)(bb12)]
2+ complexes, in both cases the
cis-α isomers and cis-β isomers (see Fig. 3) were isolated and
individually characterised. In the present case, only the cis-
α-[Ru(phen′)(bb7)]2+ isomer was isolated, and consequently the
cis,cis-[RuCl2(DMSO)2(Me4phen)] reaction with the bb7 ligand
was examined in detail. When samples were taken from the
reaction mixture during the course of the synthesis and
studied by 1H NMR, both the cis-α and cis-β isomers were
unambiguously identified in COSY spectra of the reaction
mixture. However, after either heating the reaction mixture to
200 °C (see Fig. 4) or allowing the mixture of the isolated
isomers stand at room temperature for several weeks, only the
cis-α isomer was observed. In addition, during the purification
process for the cis-α isomer for all the [Ru(phen′)(bb7)]2+ cases,
a small amount (<5% yield based upon starting material) of
[Ru(phen′)(Me2bpy)2]
2+ was observed: for phen′ = Me2phen
and Me4phen, the products were isolated and the
1H NMR and
TOF-MS (ESI+) characterisation data are provided in the ESI.†
For [Ru(Me4phen)(Me2bpy)2]
2+, the structure confirmed by
X-ray crystallography (see Fig. S1: ESI†).
The same observations were made for reactions conducted
under normal laboratory light or in the dark.
As the cis-β-[Ru(Me4phen)(bb7)]2+ complex appeared to be
less stable than the corresponding cis-α isomer, it was of inter-
est to compare the relative energies of the isomers through
DFT calculations. In addition, the differences in energies
between the cis-α and cis-β isomers for the bb7 complex were
compared to those for the corresponding bb12 complex. As
shown in Table 2, there was good agreement between the X-ray
and DFT-optimised structures based upon the cis-α-[Ru-
(Me4phen)(bb7)]
2+ N–Ru–N angles for the corresponding
chelate rings. While there were only small differences in the
N–Ru–N bond angles between the cis-α-[Ru(Me4phen)(bb7)]2+
(designated α-Me4phen-7) and the cis-α-[Ru(Me4phen)(bb12)]2+
(designated α-Me4phen-12) complexes, significant differences
were observed between the corresponding cis-β isomers (desig-
nated β-Me4phen-7 and β-Me4phen-12, respectively): see
Table 3. Furthermore, the β-Me4phen-12 complex was deter-
mined to be 5.6 kJ mol−1 less stable than the α-Me4phen-12,
whereas by contrast β-Me4phen-7 was 76.8 kJ mol−1 less stable
than the α-Me4phen-7 isomer. It is observed that the calculated
difference in the N1–Ru–N5 angle between the β-Me4phen-7
and β-Me4phen-12 species is significant (Table 3), and this
may well be the origin of the instability of the β-Me4phen-7
species relative to both the α-Me4phen-7 isomer and the
β-Me4phen-12 analogue. However, no significant differences in
the calculated Ru–N bond lengths were observed between the
α-Me4phen-7 and β-Me4phen-7 isomers.
Scheme 1 Synthesis of [Ru(phen’)(bb7)]
2+ complexes containing the bb7 ligand.
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Antimicrobial activity
The minimum inhibitory concentrations (MIC) for the ruthe-
nium complexes against six bacterial strains (methicillin-resist-
ant Staphylococcus aureus (MRSA) and a methicillin-sensitive
strain of S. aureus, both avian pathogenic (APEC) and uro-
pathogenic (UPEC) strains of Escherichia coli as well as a lab-
oratory strain (E. coli MG1655), and Pseudomonas aeruginosa
PAO1) were determined and the results are summarised in
Table 4. Interestingly, the [Ru(5-NO2phen)(bb7)]
2+ complex
(designated α-NO2phen-7) showed very little or no activity
against any of the bacterial strains. By contrast, for the
other cis-α-[Ru(phen′)(bb7)]2+ complexes, the antimicrobial
activities increased with the degree of methylation. Most
importantly, cis-α-[Ru(Me4phen)(bb7)]2+ displayed very similar
activity against all bacterial strains: for ruthenium(II)-based
complexes, the observed similarity in activity against Gram-
positive and Gram-negative is rare. In absolute terms, the cis-
α-[Ru(Me4phen)(bb7)]2+ complex exhibited comparable or
better activities to the Gram-negative species compared to cis-
α-[Ru(Me4phen)(bb12)]2+ and [Ru(Me4phen)3]2+ {designated
(Me4phen)3}. The dinuclear complexes Rubb7 and Rubb12 (see
Fig. 1) were also examined, and the results indicated that the
cis-α-[Ru(Me4phen)(bb7)]2+ complex was more active than
Rubb7, but less active than Rubb12.
The minimum bactericidal concentrations (MBC) of the
ruthenium complexes were also determined, and the results
are summarised in Table 5. Consistent with previous results,
the MBC values for Rubb12 and [Ru(Me4phen)3]
2+ were gener-
ally ≤2 × MIC, indicating that the two ruthenium complexes
are bactericidal. By contrast, cis-α-[Ru(phen)(bb12)]2+ is border-
line bactericidal/bacteriostatic. Surprisingly, the MBC values
for cis-α-[Ru(Me4phen)(bb7)]2+ show considerable variation, e.g.
S. aureus compared to MRSA, or APEC to UPEC. Based upon
the MBC/MIC ratios, cis-α-[Ru(Me4phen)(bb7)]2+ is clearly bac-
tericidal against MRSA and APEC, but bacteriostatic against
S. aureus and UPEC. These significant differences within both
the Gram-positive and Gram-negative classes of bacteria indi-
Table 1 X-Ray experimental and refinement data for cis-α-[Ru(Me4phen)(bb7)]2+ and [Ru(Me4phen)(Me2bpy)]2+
Compound cis-α-[Ru(Me4phen)(bb7)](PF6)2·3(CHCl3) (Fig. 2) [Ru(Me4phen)(Me2bpy)](PF6)2·0.25(H2O) (Fig. S1; ESI)
Empirical formula C48H51Cl9F12N6P2Ru C40H40.5F12N6O0.25P2Ru
Formula weight 1422.01 1000.29
Crystal system Monoclinic Monoclinic
Space group P21/c P21/c
a (Å) 9.853(2) 10.782(2)
b (Å) 28.124(6) 28.514(6)
c (Å) 20.632(4) 13.176(3)
α (°)
β (°) 92.25(3) 96.63(3)
γ (°)
Volume (Å3) 5713(2) 4023.7(14)
Z 4 4
Density (calc.) g m−3 1.653 1.651
Absorption coefficient (mm−1) 0.832 0.566
F(000) 2864 2026
Crystal size (mm3) 0.567 × 0.100 × 0.017 0.289 × 0.255 × 0.006
θ range for collection (°) 1.225 to 31.928 1.428 to 31.900
Reflections collected 105 036 75 249
Observed reflections [R(int)] 14 330 [0.0463] 11 496 [0.0794]
Goodness-of-fit on F2 1.049 1.036
R1 [I > 2σ(I)] 0.0488 0.0489
wR2 (all data) 0.1349 0.1272
Largest diff. peak and hole (e Å−3) 1.553, −2.055 0.535, −1.420
Fig. 2 X-ray crystal structure of the cis-α-[Ru(Me4phen)(bb7)]2+
complex.
Fig. 3 Structures of cis-α- and cis-β-[Ru(phen’)(bbn)]2+.
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cate that cis-α-[Ru(Me4phen)(bb7)]2+ has significant specific
toxicity to some bacteria and suggests that the mechanism
of the activity is considerably different compared to
[Ru(Me4phen)(bb12)]
2+, [Ru(Me4phen)3]
2+ and Rubb12.
Lipophilicity (log P)
Lipophilicity is a factor that affects the biological activity of
any metal complex because it is often correlated with the
capacity of the drug to penetrate through the cell membrane.
The standard octanol/water partition coefficients (log P) were
determined for the [Ru(phen′)(bbn)]
2+ and [Ru(Me4phen)3]
2+
complexes, and the results are summarised in Table 6. As
expected, cis-α-[Ru(Me4phen)(bb7)]2+ was more lipophilic than
the other cis-α-[Ru(phen′)(bb7)]2+ analogues. The introduction
of the nitro-substituent on 1,10-phenanthroline ligand in cis-
α-[Ru(5-NO2phen)(bb7)]2+ did not decrease the lipophilicity
compared with the cis-α-[Ru(phen)(bb7)]2+ analogue. More sig-
nificantly, the cis-α-[Ru(Me4phen)(bb7)]2+ isomer is more lipo-
philic than the Rubbn complexes, but of similar lipophilicity to
[Ru(Me4phen)3]
2+, and less lipophilic than their [Ru(phen)-
(bb12)]
2+ analogues.
Cellular accumulation
The cellular accumulations of the cis-α-[Ru(phen′)(bbn)]2+ ana-
logues (and Rubb12 and [Ru(Me4phen)3]
2+) in MRSA, UPEC and
Table 2 Comparison of angles (in degrees) in cis-α-[Ru(Me4phen)
(bb7)]
2+ X-ray crystal and DFT-optimised structures. Nomenclature is
defined in Fig. 5
Angle
α-Me4phen-7
(crystal structure)
α-Me4phen-7
(DFT) % deviation
N1–Ru–N2 78.9 77.5 1.77
N1–Ru–N3 94.6 95.5 0.95
N1–Ru–N5 97.1 97.3 0.21
N1–Ru–N6 88.9 89.5 0.67
N4–Ru–N2 94.6 95.6 1.06
N4–Ru–N3 78.5 77.4 1.40
N4–Ru–N5 89.4 89.9 0.56
N4–Ru–N6 98.2 97.8 0.41
N2–Ru–N6 100.6 99.5 1.09
N2–Ru–N3 82.1 83.7 1.95
N3–Ru–N5 98.4 99.1 0.71
N3–Ru–N6 176.0 174.6 0.80
Table 3 Comparison of angles (in degrees) in all DFT-optimised structures. Nomenclature is defined in Fig. 5
Angle α-Me4phen-7 α-Me4phen-12 β-Me4phen-7 β-Me4phen-12 [Ru(Me2bpy)2-(Me4phen)]2+
N1–Ru–N2 77.5 77.3 76.9 77.4 77.2
N1–Ru–N3 95.5 98.1 89.2 88.8 89.6
N1–Ru–N5 97.3 96.5 103.9 99.1 97.5
N1–Ru–N6 89.5 88.4 96.5 97.2 96.4
N4–Ru–N2 95.6 98.0 96.2 96.7 97.3
N4–Ru–N3 77.4 77.3 97.2 96.5 96.5
N4–Ru–N5 89.9 88.4 84.2 87.3 88.4
N4–Ru–N6 97.8 96.4 77.6 77.9 78.0
N2–Ru–N6 99.5 97.6 94.2 89.3 88.1
N2–Ru–N3 83.7 87.3 91.0 96.6 98.2
N3–Ru–N5 99.1 97.7 75.8 77.3 77.2
N3–Ru–N6 174.6 172.6 173.0 172.3 172.1
Fig. 4 Aromatic region of the 1H NMR spectra of cis-α and cis-β isomers of [Ru(Me4phen)(bb7)]2+ and reaction mixtures in CD3CN at different reac-
tion conditions. (a) Isolated mixture of the cis-α and cis-β isomers (sample from reaction after 2 h at 130–140 °C). (b) Isolated products from reaction
(Scheme 1) after 1 h at 130–140 °C. (c) Isolated products from reaction (Scheme 1) after 1 h at 130–140 °C and then a second hour at ∼200 °C.
(d) cis-α-[Ru(Me4phen)(bb7)]2+ and (e) [Ru(Me4phen)(Me2bpy)]2+.
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PAO1 were determined by measuring the concentration of the
complex remaining in the culture supernatant after removing
the bacteria by centrifugation. The concentration of the ruthe-
nium complex in the supernatant was calculated from a
luminescence calibration curve obtained by adding known
concentrations of the ruthenium complex to a blank super-
natant. As the luminescence of the ruthenium complexes
varied with the different broths and supernatants for each bac-
terial strain, a calibration curve was determined for each
complex in the supernatant of each bacterial strain.
Fig. 6 shows the cellular accumulation of the ruthenium
complexes against MRSA, UPEC and PAO1 at various time
points. The uptake of the ruthenium complexes was greater
with the Gram-positive bacteria compared with the Gram-nega-
tive strains, with PAO1 showing the lowest accumulation – con-
sistent with the observed MIC/MBC values. In addition, while
the accumulation in Gram-positive bacteria gradually
increased with time for all complexes, the same result was not
observed for the Gram-negative bacteria strains. Interestingly,
the cellular accumulation of the cis-α-[Ru(Me4phen)(bb7)]2+
and [Ru(Me4phen)3]
2+ in PAO1 reached its highest within
15 minutes and then maintained this level; in contrast, the
accumulation of Rubb12 and cis-α-[Ru(phen)(bb12)]2+ steadily
increased over the two hours. Moreover, the uptake of the cis-
α-[Ru(phen′)(bb7)]2+ family is consistent with the MIC/MBC
values, with the degree of methylation of the phen ligand cor-
related with the accumulation. However, there was signifi-
cantly less accumulation of cis-α-[Ru(Me4phen)(bb7)]2+ in PAO1
than with [Ru(Me4phen)3]
2+, cis-α-[Ru(phen)(bb12)]2+ and
Rubb12 despite the activity for cis-α-[Ru(Me4phen)(bb7)]2+
Table 4 MIC values (µg mL−1) for the ruthenium complexes after a 16–18 hours incubation against Gram-positive and Gram-negative bacteria
Compound
Gram-positive Gram-negative
S. aureus MRSA E. coli MG1655 E. coli APEC E. coli UPEC P. aeruginosa PAO1
α-phen-7 8 16 >128 >128 >128 >128
α-Me2phen-7 8 8 32 64 128 >128
α-Me4phen-7 4 4 4 8 8 8
α-NO2phen-7 128 128 >128 >128 >128 >128
α-phen-12 1–2 2 4 8 8 16
β-phen-12 2 2 8 16 16 32
(Me4phen)3 0.5–1 0.5 4 4 8 32
Rubb7 8 8 16 4 16 128
Rubb12 2 2 2 2 2 16
Gentamicin 0.25 0.25 0.5 0.5 1 0.25
Fig. 5 Atom label nomenclature for the ruthenium complexes in this work, shown for [Ru(phen’)(bbn)]
2+ {where phen’ = Me4phen (shown bolded);
bbn = bb7} and [Ru(Me2bpy)2(Me4phen)]
2+. Carbon chain lengths of n = 7 and 12 were calculated for cis-α- and cis-β-[Ru(Me4phen)(bbn)]2+.
Table 5 MBC values (µg mL−1) for the ruthenium complexes against
Gram-positive and Gram-negative bacterial strains
Compound
Gram-positive Gram-negative
S. aureus MRSA MG1655 APEC UPEC PAO1
α-phen-7 64 16 >128 >128 >128 >128
α-Me2phen-7 64 16 ≥128 ≥128 >128 >128
α-Me4phen-7 64 4 32–64 16 >128 ≥128
α-NO2phen-7 128 ≥128 >128 >128 >128 >128
α-phen-12 4 2 8–16 32 32 ≥64
β-phen-12 4–8 8 16–32 32 32 128
(Me4phen)3 1 1 8 8 16–32 64
Rubb7 ≥32 ≥16 32 32 64 >128
Rubb12 2 2 2 2 2–4 64
Gentamicin 2 1 2 1 4 1
Table 6 Octanol/water partition coefficients (log P) for the ruthenium
complexes
Metal complex Charge log P
α-phen-7 2 −1.83 ± 0.04
α-Me2phen-7 2 −1.41 ± 0.07
α-Me4phen-7 2 −1.33 ± 0.03
α-NO2phen-7 2 −1.58 ± 0.09
α-phen-12a 2 −0.9
β-phen-12a 2 −1.0
(Me4phen)3
a 2 −1.35
Rubb7
b 4 −3.4
Rubb12
b 4 −2.7
Rubb10
b 4 −3.3
a Results from ref. 10. b Results from ref. 7.
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being two- to four-fold higher than for the other three
complexes.
Interaction with DNA
As previous studies showed that the di-, tri- and tetra-nuclear
ruthenium complexes linked by the bbn ligand preferentially
localise with DNA and RNA in bacterial and eukaryotic
cells,18,19 it was of interest to examine the DNA binding affinity
of the [Ru(phen′)(bbn)]
2+ complexes to DNA. The binding
of the ruthenium complexes to calf-thymus (CT)-DNA was
examined by UV/Vis spectroscopy and the intrinsic binding
constants K to DNA calculated by a non-linear least-square
method using eqn (1).20
ðεa  εfÞ=ðεb  εfÞ ¼ ðb ðb 2  2K 2Ct½DNA=sÞ1=2Þ=2KCt ð1aÞ
b ¼ 1þ KCt þ K ½DNA=2s ð1bÞ
where [DNA] is the concentration of DNA in M (nucleotide); εa
is the molar absorption coefficient observed for the 1MLCT
absorption band at a given DNA concentration; εf is the molar
absorption coefficient of the free complex without DNA; εb is
the molar absorption coefficient of the complex fully bound to
DNA; K is the equilibrium-binding constant in M−1; and Ct is
the total metal complex concentration and s is the binding site
size.
All [Ru(phen′)(bbn)]
2+ complexes showed strong binding to
CT-DNA, with binding constants of approximately 1 × 107 M−1
(see Table 7). As the DNA binding affinities were surprisingly
strong, the well-known high affinity metallointercalator
complex [Ru(phen)2(dppz)]
2+ (ref. 21) was examined as a
control. The observed binding constant, 2 × 106 M−1, was com-
parable with previously reported values.20,21 The cis-α-[Ru(5-
NO2phen)(bb7)]
2+ complex exhibited the strongest binding
affinity. However, no significant differences in the DNA
binding affinities between the cis-α-[Ru(phen)(bb7)]2+ and cis-
α-[Ru(Me4phen)(bb7)]2+ complexes were observed. In addition,
the binding constants of cis-α-[Ru(phen′)(bb7)]2+ isomers are
higher than for the [Ru(phen)(bb12)]
2+ analogues, which is
consistent with reported values for the DNA binding affinities
for [Ru(phen)(bb10)]
2+ and [Ru(phen)(bb12)]
2+ analogues.17
Discussion
Due to the emergence of drug-resistant bacteria there is a need
to develop new classes of antimicrobial agents. We have pre-
viously shown17 that ruthenium(II) complexes containing bis-
[4(4′-methyl-2,2′-bipyridyl)]-1,n-alkane (bbn; for n = 10 and 12)
as a tetradentate ligand in a mononuclear complex (rather
than as a bridging ligand in oligonuclear complexes) exhibit
excellent antimicrobial activity in terms of MIC values, against
both Gram-positive and Gram-negative bacteria. In this study
Fig. 6 Cellular accumulation of the cis-α-[Ru(phen’)(bb7)]2+, [Ru(Me4phen)3]2+ and Rubb12 complexes into bacteria after incubation for 15, 30, 60,
90 and 120 minutes.
Table 7 The CT-DNA binding constants (K) of the mononuclear ruthe-
nium complexes
Complexes K [M−1] × 107
α-phen-7 1.73 ± 0.26
α-Me2phen-7 0.42 ± 0.04
α-Me4phen-7 1.46 ± 0.47
α-NO2phen-7 4.22 ± 0.93
α-phen-12 0.59 ± 0.05
β-phen-12 0.20 ± 0.02
(phen)2dppz 0.21 ± 0.05
(Me4phen)3 0.25 ± 0.01
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we have extended the [Ru(phen)(bbn)]
2+ family of complexes by
altering both the bbn and phen ligands, and report their anti-
microbial activities in terms of both MIC and MBC values.
In the syntheses of the [Ru(phen′)(bb7)]
2+ complexes, both
the cis-α and cis-β isomers were initially observed. However, in
contrast to the bb10 and bb12 homologues of [Ru(phen)bbn]
2+,
the cis-β isomer was not stable and converted predominantly
to the cis-α isomer over time or in harsh conditions. It is con-
cluded that the cis-β is a kinetic product but the cis-α is the
thermodynamic product. The DFT calculations demonstrated
that the cis-β complex is highly strained and considerably less
stable than the corresponding cis-α isomer. As ruthenium(II)
complexes with three bidentate chelating ligands groups (as is
essentially the case in [Ru(phen′)(bb7)]
2+ – but with an
additional chelate ring involving the polymethylene chain in
the tetradendate bb7) are considered to be “kinetically inert”
the conversion from the cis-β to the cis-α is unusual, although
isomerisation of ruthenium(II) complexes with monodentate
ligands, e.g. pyridine, is well known.22 Examples of photoacti-
vated isomerisation, ligand loss and degradation of tris(biden-
tate) complexes, e.g. [Ru(bpy)3]
2+, are known23 and it has been
suggested that ruthenium(II) complexes with distorted octa-
hedral geometry photodecompose through ligand dis-
sociation.24 The present DFT calculations have indicated that
the cis-β-[Ru(Me4phen)(bb7)]2+ complex is unstable and the
octahedral geometry is distorted: consequently, the cis-β and
cis-α isomers can interconvert but demonstrably by a thermal
mechanism in this case, as the presence of light does not
affect the process.
The MIC/MBC values presented in this study demonstrate
that apart from cis-α-[Ru(5-NO2phen)(bb7)]2+, the cis-α-
[Ru(phen′)(bb7)]
2+ complexes are active against Gram-positive
bacteria but exhibit variable activity towards Gram-negative
species. However, the cis-α-[Ru(Me4-phen)(bb7)]2+ complex
shows good activity (MICs ≤ 8 μg mL−1) against both Gram-
positive and Gram-negative bacteria, including the notoriously
drug-resistant P. aeruginosa. Ruthenium(II) complexes,12,16 like
most antimicrobial agents,25 have generally not shown good
activity against P. aeruginosa. Recently we reported that the cis-
α-[Ru(phen)(bb12)]2+ complex does readily accumulate in
P. aeruginosa and exhibits good activity against this bacterial
strain.17 The results of the current study indicate that cis-α-
[Ru(Me4phen)(bb7)]
2+ is slightly more active (in terms of MIC)
against P. aeruginosa than cis-α-[Ru(phen)(bb12)]2+. However, a
sixteen-fold difference between the MBC and MIC values for
cis-α-[Ru(Me4phen)(bb7)]2+ against P. aeruginosa was observed,
compared to the two-fold difference for [Ru(Me4phen)3]
2+ and
a four-fold difference for cis-α-[Ru(phen)(bb12)]2+. This
suggests the cis-α-[Ru(Me4phen)(bb7)]2+ complex may exert its
antimicrobial activity through a different mechanism.
Furthermore, and of note, of all the mono-, di-, tri- and tetra-
nuclear ruthenium complexes that incorporate the bbn ligand
that we have examined,12–17 the cis-α-[Ru(Me4phen)(bb7)]2+
complex displays the most similar MIC values but the most
varied MBC values across a range of Gram-positive and Gram-
negative bacteria. This is also consistent with the cis-α-
[Ru(Me4phen)(bb7)]
2+ complex exerting its antimicrobial activity
through a different mechanism. Alternatively, the highly vari-
able MBC values observed for cis-α-[Ru(Me4phen)(bb7)]2+ could
be due to different resistance mechanisms – e.g. the up-regu-
lation of efflux pumps and plasmid-mediated resistance
mechanisms – that exist between bacteria, even closely related
bacteria such as the E. coli strains UPEC and APEC.
While we have previously reported the antimicrobial activi-
ties of mono- and oligo-nuclear ruthenium complexes that
incorporate the bbn ligand, the present study also examined
the effects of substituents on the 1,10-phenanthroline ligand.
The antimicrobial activities were examined in relationship to
the electron-withdrawing/-donating effect of substituents on
the phenanthroline ligand through the analyses of their
respective cellular accumulations and DNA binding. The
results clearly demonstrate the importance of both cellular
accumulation and DNA binding. The cis-α-[Ru(5-NO2phen)-
(bb7)]
2+ complex bound DNA with the highest affinity but dis-
played no antimicrobial activity because it was not taken up by
the bacterial cells. Given that cis-α-[Ru(5-NO2phen)(bb7)]2+ is
slightly more lipophilic than cis-α-[Ru(phen)(bb7)]2+, the lack
of uptake and antimicrobial activity of the nitro-substituted
complex suggests that relatively minor charges of the charge
density on the ruthenium centre play a critical role in the
diffusion of the ruthenium complex across the bacterial mem-
brane. The introduction of methyl substituents on the 1,10-
phenanthroline progressively increased the cellular accumu-
lation and antimicrobial activities of the cis-α-[Ru(phen′)-
(bb7)]
2+ complexes, especially against Gram-negative bacteria.
All the ruthenium complexes showed better accumulation
in the Gram-positive than the Gram-negative bacteria,
suggesting a clear relationship between the cellular accumu-
lation and MIC, but only to a point. The cis-α-[Ru(phen)-
(bb12)]
2+ exhibited similar antimicrobial activity but a higher
level of cellular accumulation than the cis-α-[Ru(phen)(bb7)]2+
across the bacteria, consistent with increasing lipophilicity
(log P = −0.9 and −1.83 respectively). Furthermore, cis-α-[Ru-
(Me4phen)(bb7)]
2+ has similar or even higher activity against
Gram-negative bacteria than [Ru(Me4phen)3]
2+ in terms of
MIC, but cis-α-[Ru(Me4phen)(bb7)]2+ showed lower cellular
accumulation in the Gram-negative bacteria compared to
[Ru(Me4phen)3]
2+. Notably, there was a different pattern of
accumulation in P. aeruginosa between the cis-α-[Ru(Me4phen)-
(bb7)]
2+ and [Ru(Me4phen)3]
2+ complexes compared with the
cis-α-[Ru(phen)(bb12)]2+ and Rubb12 complexes. The uptake of
the latter two complexes steadily increased over the two-hour
time period; whereas for the former complexes, maximum
accumulation was achieved at the first time point (15 minutes),
with the cellular accumulation then remaining constant up to
two hours. These results potentially suggest that P. aeruginosa
may have an effective efflux pump against the cis-α-[Ru(Me4phen)-
(bb7)]
2+ and [Ru(Me4phen)3]
2+ complexes, or that the ruthe-
nium complexes incorporating the bb12 ligand can permeabi-
lise the bacterial membrane.
The cis-α-[Ru(phen′)(bb7)]2+ complexes showed surprisingly
high DNA binding affinity, even binding more strongly
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than the established high-affinity metallointercalator
[Ru(phen)2(dppz)]
2+. The high DNA binding affinity of the cis-
α-[Ru(phen′)(bb7)]2+ complexes is likely to be due to an
increased hydrophobic effect coupled with the decreased
ability of the complexes to self-associate in water due to steric
clashes between the methyl groups. The observations that cis-
α-[Ru(Me4phen)(bb7)]2+ shows lower accumulation but exhibits
the same or slightly better antimicrobial activities against the
Gram-negative bacteria than the [Ru(Me4phen)3]
2+ or cis-α-
[Ru(phen)(bb12)]
2+ complexes could suggest DNA (and RNA)
binding is at least one aspect of the antimicrobial activity.
Indeed, we have previously demonstrated that the dinuclear
and oligonuclear ruthenium complexes target DNA and RNA
in bacteria and eukaryotic cells.18,19 However, the mechanism
of action for kinetically-inert polypyridylruthenium(II) com-
plexes is still a matter of debate. In addition to nucleic acid
binding, a variety of studies have proposed that these ruthe-
nium complexes can permeabilise the bacterial mem-
brane,26,27 inhibit the activity of important enzymes,28 or
induce the production of reactive oxygen species (ROS) that
could cause DNA damage and bacterial cell death.29 It is likely
that for each ruthenium complex a number of these potential
mechanisms are simultaneously active, with the balance
between the various mechanisms modulated by the specific
chemical structure.
Conclusions
The mononuclear cis-α-[Ru(Me4phen)(bb7)]2+ complex has sig-
nificant potential as an antimicrobial agent. In this study, it
has been shown that it is highly active against P. aeruginosa.
Our results also suggest that the antimicrobial activity differ-
ences between the cis-α-[Ru(phen′)(bb7)]2+ complex and the
mononuclear [Ru(phen)(bb12)]
2+ complexes previously studied
are significant in terms of the electron density imposed by
substituents on the 1,10-phenanthroline ligand. As a con-
sequence, and given that the structure can be readily modified,
it is possible that ruthenium(II) complexes can be customised
to particular bacteria. Our studies continue on this project: the
toxicity on eukaryotic cells of [Ru(phen′)(bbn)]
2+ species will be
explored and a further probe of the working mechanisms of
this class of ruthenium complexes is on the way.
Experimental
Physical measurements
1H and 13C NMR spectra were recorded on a Varian Advance
400 MHz spectrometer at room temperature {CDCl3 (99.8%,
CIL), CD3CN (>99.8%, Aldrich), or CD3OD (>99.8%, Aldrich)}.
Luminescence was measured on a Cary Eclipse Fluorescence
Spectrophotometer with λex = 488 nm: emission spectra were
collected from λem = 500–800 nm. Absorbance (200–600 nm)
was measured on a VARIAN CARY 50 Probe UV–visible spectro-
photometer. Mass-spectroscopic analysis was performed by
the RSC Mass-Spectrometry Facility (Research School of
Chemistry, Australian National University, Canberra), and the
Campbell Microanalytical Laboratory (Chemistry Department,
University of Otago) performed the microanalyses.
Materials and methods
Potassium hexafluorophosphate (KPF6), and 1,10-phenanthro-
line and its derivatives, were purchased from Aldrich and used
as supplied. Amberlite IRA-402 (chloride form) anion-exchange
resin and SP Sephadex C-25 cation exchanger were obtained
from GE Health Care Bioscience. Cation-adjusted Mueller–
Hinton broth (CAMHB), Mueller–Hinton Agar2 and the anti-
biotic gentamicin were purchased from Sigma-Aldrich (UK).
LB broth was purchased from Formedium (UK).
The syntheses of ligands bbn (n = 7, 12) and cis-
[RuCl2(DMSO)4] were performed according to previously
reported methods.30,31
Syntheses of metal complexes
cis,cis-[RuCl2(DMSO)2(phen′)]. cis,cis-[RuCl2(DMSO)2(phen′)]
complexes were synthesised using schemes based on pre-
viously reported methods.32 A suspension of 1 mmol of cis-
[RuCl2(DMSO)] and 1 mmol of the appropriate substituted
1,10-phenanthroline was refluxed in toluene (10 mL) for 2 h.
The solid that separated was filtered and washed with toluene
and then with diethylether. For cis,cis-[RuCl2(DMSO)2(phen)], cis,-
cis-[RuCl2(DMSO)2(Me4phen)] and cis,cis-[RuCl2(DMSO)2-
(5-NO2phen)], the pure product was realised after filtration.
For cis,cis-[RuCl2(DMSO)2(Me2phen)], after filtration the crude
product was dissolved in a minimal volume of dichloro-
methane (DCM) and then loaded onto a silica gel column
(230–400 mesh; 3 cm diam). The desired product and side pro-
ducts were gradient-eluted using 1–4% (v/v) methanol in DCM.
The purity and contents of each fraction were determined by
TLC (silica gel), using 5% (v/v) methanol in DCM as eluent.
The purest fractions were combined and the solvent was
removed in vacuo to give light yellow-green solids: yields: cis,-
cis-[RuCl2(DMSO)2(phen)], yellow-green powder – 83%; cis,cis-
[RuCl2(DMSO)2(Me4phen)], green-brown powder – 85%; cis,cis-
[RuCl2(DMSO)2(Me2phen)], light yellow-green powder – 70%;
cis,cis-[RuCl2(DMSO)2(5-NO2phen)], brown powder – 90%.
cis,cis-[RuCl2(DMSO)2(phen)]. The
1H NMR and mass-spec-
tral data were consistent with that reported previously for this
complex.33
cis,cis-[RuCl2(DMSO)2(Me2phen)]. Anal. calcd for
C18H24Cl2N2O2RuS2: C, 40.3%; H, 4.51%; N, 5.2%. Found: C,
40.9%; H, 4.60%; N, 5.1%. 1H NMR (400 MHz, CDCl3): δ 9.96
(d, J = 5.6 Hz, 1H; H2 or H9); 9.80 (d, J = 5.6 Hz, 1H; H2 or H9);
8.14 (d, J = 9.6 Hz, 1H; H5 or H6); 8.10 (d, J = 9.2 Hz, 1H; H5 or
H6); 7.74 (d, J = 5.6 Hz, 1H; H3 or H8); 7.57 (d, J = 5.6 Hz, 1H;
H3 or H8); 3.58 (d, J = 10.8 Hz, 6H; 2 × CH3); 3.15 (s, 3H;
S(CH3)); 2.93 (s, 3H; S(CH3)), 2.87 (s, 3H; S(CH3)); 2.50 (s, 3H;
S(CH3)). TOF MS (ESI+): most abundant ion found for [M +
Na]+, m/z 559.0. Calc. for Ru[C18H24Cl2N2NaO2S2]
+, m/z 558.96.
cis,cis-[RuCl2(DMSO)2(Me4phen)]. Anal. calcd for
C20H28Cl2N2O2RuS2: C, 42.6%; H, 5.00%; N, 5.0%. Found: C,
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42.1%; H, 4.91%; N, 5.0%. 1H NMR (400 MHz, CDCl3): δ 9.80
(s, 1H; H2 or H9); 9.75 (s, 1H; H2 or H9); 8.14 (d, J = 9.2 Hz,
1H; H5 or H6); 8.10 (d, J = 9.2 Hz, 1H; H5 or H6); 3.61 (d, J =
7.2 Hz, 6H; 2 × CH3); 3.18 (s, 3H; S(CH3)); 2.76 (s, 6H; 2 ×
CH3); 2.65 (s, 3H; S(CH3)); 2.60 (s, 3H; S(CH3)); 2.41
(s, 3H; S(CH3)). TOF MS (ESI+): most abundant ion found for
[M + Na]+, m/z 587.0. Calc. for Ru[C20H28Cl2N2NaO2S2]
+, m/z
586.99.
cis,cis-[RuCl2(DMSO)2(5-NO2phen)]·H2O. Anal. calcd for
C16H21Cl2N3O5RuS2: C, 33.6%; H, 3.70%; N, 7.4%. Found: C,
33.5%; H, 3.59%; N, 7.3%. 1H NMR (400 MHz, CDCl3): δ 10.33
(dd, J = 1.2, 5.2 Hz, 1H; H2 or H9, one isomer); 10.30 (dd, J =
1.6, 5.6 Hz, 1H; H2 or H9, another isomer); 10.17 (dd, J = 1.2,
5.6 Hz, 1H; H2 or H9, one isomer); 10.10 (dd, J = 0.8, 5.2 Hz,
1H; H2 or H9, another isomer); 9.33 (dd, J = 1.2, 8.4 Hz, 1H;
H4 or H7, one isomer); 9.18 (dd, J = 1.2, 8.8 Hz, 1H; H4 or H7,
another isomer); 8.92 (d, J = 5.2 Hz, 1H, H6 for two isomers);
8.68 (dd, J = 1.2, 8.0 Hz, 1H; H4 or H7, one isomer); 8.56 (dd,
J = 1.2, 7.6 Hz, 1H; H4 or H7, another isomer); 8.12 (m, 2H,
H3/H8, one isomer); 7.94 (m, 2H, H3/H8, another isomer);
3.61 (d, J = 2 Hz, 6H; 2 × CH3, one isomer); 3.57 (d, J = 4.4 Hz,
6H; 2 × CH3, another isomer); 3.23 (s, 3H; S(CH3), one isomer);
3.20 (s, 3H; S(CH3); another isomer); 2.75 (s, 3H; S(CH3), one
isomer); 2.66 (s, 3H; S(CH3), another isomer). TOF MS (ESI+):
most abundant ion found for [M + Na]+, m/z 575.9. Calc. for
Ru[C16H19Cl2N3NaO4S2]
+, m/z 575.91.
[Ru(phen′)(bb7)](PF6)2
A solution of cis,cis-[RuCl2(DMSO)2(phen′)] {where phen′ =
phen; Me2phen; Me4phen; and 5-NO2phen} (0.39 mmol) and
the bb7 ligand (0.47 mmol) in N2-purged ethylene glycol
(35 mL) was heated to 130–140 °C and stirred in an N2 atmo-
sphere for 2 h. The reaction mixture turned from light green to
bright orange during the course of the reaction. The reaction
mixture was cooled to room temperature and water (10 mL)
was added to the bright-orange solution, which was then
loaded onto a SP Sephadex C-25 cation-exchange column (3 ×
20 cm). The column was washed with water and the desired
mononuclear complex was eluted with aqueous NaCl solution
(0.3 M). Solid KPF6 (ca. 5 mg) was added to the eluate and the
complex was extracted into DCM (2 × 30 mL). The organic layer
was washed with water (20 mL), dried over anhydrous Na2SO4
and evaporated to dryness to obtain the PF6
− salt of the
complex. The complex was further purified by recrystallisation
from acetonitrile/diethyl ether to obtain a bright-red/orange
solid of [Ru(phen′)(bbn)](PF6)2. Typical yields were approxi-
mately 20–25%. For cis-[RuCl2(DMSO)2(Me2phen)(bb7)](PF6)2
and cis [RuCl2(DMSO)2(Me4-phen)(bb7)](PF6)2, after recrystalli-
sation, the symmetrical isomers were purified by the long SP
Sephadex C-25 cation-exchange column (1.5 × 90 cm).
Purification of cis-α isomers
[RuCl2(DMSO)2(Me2phen)(bb7)] or [RuCl2(DMSO)2(Me4phen)
(bb7)](PF6)2 (35 mg) was converted into the chloride salt by stir-
ring in methanol with Amberlite IRA-402 (chloride form)
anion-exchange resin for 1 h. After removal of the resin by fil-
tration, the methanol filtrate was evaporated and the resultant
chloride salt was dissolved in water (20 mL) and loaded onto a
SP Sephadex C-25 cation-exchange column (1.5 × 90 cm). The
cis-α isomers and impurities were eluted as separate bands
with an aqueous solution of sodium toluene-4-sulfonate
(0.125 M) as the eluent. Solid KPF6 was added to the eluents
and the complexes were extracted into DCM (2 × 20 mL). The
organic layer was washed with water (20 mL), dried over an-
hydrous Na2SO4, and evaporated to dryness to obtain the PF6
salt of the complex.
cis-α-[Ru(phen)(bb7)](PF6)2·CH2Cl2. Anal. calcd for
C42H42Cl2F12N6P2Ru: C, 46.2%; H, 3.87%; N, 7.7%. Found: C,
46.3%; H, 3.90%; N, 7.6%. 1H NMR (400 MHz, CD3CN): δ 8.66
(dd, J = 1.2, 8.4 Hz, 2H; H2/H9); 8.63 (dd, J = 1.2, 5.2 Hz, 2H;
H4/H7); 8.32 (s, 2H; H5/H6); 8.28 (br s, 2H; bipy3); 8.15 (d, J =
1.2 Hz, 2H, bipy3′); 7.74 (dd, J = 5.2, 8.0 Hz, 2H, H3/H8); 7.47
(d, J = 6 Hz, 2H; bipy6′); 7.16(d, J = 5.6 Hz, 2H; bipy6); 7.08 (dd,
J = 2.0, 6.0 Hz, 2H; bipy5′); 7.00 (dd, J = 1.2, 6.0 Hz, 2H; bipy5);
2.77–2.83 (m, 2H; CH2, bipy); 2.60–2.67 (m, 2H; CH2, bipy);
2.48 (s, 6H; CH3 bipy); 1.58–1.69 (m, 2H; CH2, bipy); 1.37–1.47
(m, 2H; CH2, bipy); 0.91–0.97 (m, 2H; CH2, bipy); 0.66–0.83 (m,
4H; 2 × CH2, bipy). TOF MS (ESI+): most abundant ion found
for [M − 2PF6]2+, m/z 359.12. Calc. for Ru[C41H40N6]2+, m/z
359.12; most abundant ion found for ([M − PF6] +), m/z 863.20.
Calc. for Ru[C41H40N6(PF6)]
+, m/z 863.21.
cis-α-[Ru(Me2phen)(bb7)](PF6)2. Anal. calcd for
C43H44F12N6P2Ru: C, 49.9%; H, 4.28%; N, 8.1%. Found: C,
49.4%; H, 4.37%; N, 8.1%. 1H NMR (400 MHz, CD3CN): δ 8.45
(t, J = 5.6 Hz, 4H; H2/H9 & H5/H6); 8.27 (br s, 2H; bipy3); 8.13
(d, J = 1.2 Hz, 2H, bipy3′); 7.57 (dd, J = 5.6, 0.8 Hz, 2H, H3/H8);
7.46 (d, J = 5.6 Hz, 2H; bipy6′); 7.16 (d, J = 5.6 Hz, 2H; bipy6);
7.06 (dd, J = 1.6, 5.6 Hz, 2H; bipy5′); 7.00 (dd, J = 1.2, 6.0 Hz,
2H; bipy5); 2.95 (s, 6H; CH3 Me2phen); 2.76–2.82 (m, 2H; CH2,
bipy); 2.60–2.66 (m, 2H; CH2, bipy); 2.47 (s, 6H; CH3 bipy);
1.60–1.68 (m, 2H; CH2, bipy); 1.37–1.46 (m, 2H; CH2, bipy);
0.90–0.97 (m, 2H; CH2, bipy); 0.63–0.82 (m, 4H; 2 × CH2, bipy).
TOF MS (ESI+): most abundant ion found for [M − 2PF6]2+, m/z
373.2. Calc. for Ru[C43H44N6Ru]
2+, m/z 373.0. Most abundant
ion found for ([M − PF6] +), m/z 891.30. Calc. for
Ru[C43H44N6(PF6)]
+, m/z 890.88.
cis-α-[Ru(Me4phen)(bb7)](PF6)2·CH2Cl2. Anal. calcd for
C46H50Cl2F12N6P2Ru: C, 48.1%; H, 4.39%; N, 7.3%. Found: C,
48.2%; H, 4.44%; N, 7.7%. 1H NMR (400 MHz, CD3CN): δ 8.43
(s, 2H; H2/H9); 8.32 (s, 2H, H5/H6); 8.27 (s, 2H; bipy3); 8.13 (s,
2H, bipy3′); 7.45 (d, J = 6.0 Hz, 2H; bipy6′); 7.16 (d, J = 5.6 Hz,
2H; bipy6); 7.06 (dd, J = 1.6, 4.4 Hz, 2H; bipy5′); 7.00 (dd, J =
0.8, 5.2 Hz, 2H; bipy5); 2.83 (s, 6H, CH3 Me4phen); 2.77–2.79
(m, 2H; CH2, bipy); 2.60–2.66 (m, 2H; CH2, bipy); 2.48 (s, 6H;
CH3 bipy); 2.36 (s, 6H, CH3 Me4phen); 1.60–1.69 (m, 2H; CH2,
bipy); 1.38–1.47 (m, 2H; CH2, bipy); 0.92–0.98 (m, 2H; CH2,
bipy); 0.67–0.83 (m, 4H; 2 × CH2, bipy). TOF MS (ESI+): most
abundant ion found for [M − 2PF6]2+, m/z 387.2. Calc. for
Ru[C45H48N6Ru]
2+, m/z 387.1. Most abundant ion found for
[M − PF6]2+, m/z 919.3. Calc for Ru[C45H48N6(PF6)]+, m/z 919.3.
cis-α-[Ru(5-NO2phen)(bb7)](PF6)2·1.5CH2Cl2. Anal. calcd for
C41.5H44Cl3F12N7O2P2Ru: C, 43.3%; H, 3.59%; N, 8.3%. Found:
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C, 43.2%; H, 3.61%; N, 8.5%. 1H NMR (400 MHz, CD3CN):
δ 9.22 (s, 1H, H6); 9.13 (d, J = 8.4 Hz, 2H; H2); 8.80 (dd, J = 3.2,
8.4 Hz, 2H; H4/H7); 8.75 (d, J = 5.6 Hz, 1H, H9); 8.29 (s, 2H;
bipy3′); 8.15 (s, 2H, bipy3); 7.62–7.88 (m, 2H, H3/H8); 7.45 (d,
J = 6.0 Hz, 2H; bipy6′); 7.19 (d, J = 5.6 Hz, 2H; bipy6); 7.10 (dd,
J = 1.6, 5.6 Hz, 2H; bipy5′); 7.03 (d, J = 6.0 Hz, 2H; bipy5);
2.77–2.83 (m, 2H; CH2, bipy); 2.62–2.67 (m, 2H; CH2, bipy);
2.49 (s, 6H; CH3 bipy); 1.60–1.67 (m, 2H; CH2, bipy); 1.41–1.45
(m, 2H; CH2, bipy); 0.91–0.96 (m, 2H; CH2, bipy); 0.72–0.79
(m, 4H; 2 × CH2, bipy). TOF MS (ESI+): +: most abundant
ion found for [M − 2PF6]2+, m/z 381.60. Calc. for
Ru[C41H39N7O2]
2+, m/z 381.61. Most abundant ion found for
[M − PF6]+, m/z 908.20. Calc. for Ru[C41H39N7O2(PF6)], m/z
908.16.
Density functional theory calculations
The geometries of five ruthenium metal complexes – cis-α- and
cis-β-[Ru(Me4phen)(bbn)]2+ (n = 7 and 12) and [Ru(Me2bpy)2
(Me4phen)]
2+ – were optimised with density functional theory
(DFT) using QCHEM 4.434 at the B3LYP/6-311G(d,p)35,36 level
of theory with the LANL2DZ effective core potential37 used for
ruthenium atoms. Calculations were carried out for both low-
and high-spin electronic configurations of the complexes, with
the low-spin state (multiplicity 1 and net charge 2) found to have
the lower energy in all five cases, as expected for d6 octahedral
ruthenium complexes. Initial structures for cis-α-[Ru(Me4phen)-
(bb7)]
2+ and [Ru(Me2bpy)2(Me4phen)]
2+ were obtained from
crystal structures and were used to build the initial structures
for cis-α-[Ru(Me4phen)(bb12)]2+, cis-β-[Ru(Me4phen)(bb7)]2+ and
cis-β-[Ru(Me4phen)(bb12)]2+ using Materials Studio 5.0.38
Single crystal X-ray diffraction
Crystals of compounds [Ru(Me4phen)(bb7)](PF6)2·3CHCl3 and
[Ru(Me4phen)(Me2bpy)2](PF6)2 suitable for X-ray crystallo-
graphic studies were grown by slow diffusion of toluene into a
chloroform solution of [Ru(Me4phen)(bb7)](PF6)2, and hexane
into a DCM solution of [Ru(Me4phen)(Me2bpy)2](PF6)2, respect-
ively. [Ru(Me4phen)(bb7)](PF6)2·3CHCl3 crystallised as orange
rod-shaped crystals and [Ru(Me4phen)(Me2bpy)2](PF6)2 as
orange plate-like crystals. Single crystals were selected and
mounted on a nylon loop in paratone-N cryo-protectant.
Single-crystal X-ray diffraction was performed at 100(2) K on
the MX-1 beamline of the Australian Synchrotron (λ =
0.7107 Å).39 Data sets were corrected for absorption using a
multi-scan method, and structures were solved by direct
methods using SHELXS-2014 and refined by full-matrix least
squares on F2 by SHELXL-2014,40 interfaced through the
program X-Seed.41 In general, all non-hydrogen atoms were
refined anisotropically and hydrogen atoms were included as
invariants at geometrically estimated positions, unless speci-
fied otherwise.
CIF data have been deposited with the Cambridge
Crystallographic Data Centre, CCDC reference numbers 1559396
and 1558934† {where [Ru(Me4phen)(bb7)](PF6)2·3CHCl3 =
1559396 and [Ru(Me4phen)(Me2bpy)2](PF6)2 = 1558934}.
Special refinement details
Compound [Ru(Me4phen)(bb7)](PF6)2 crystallises with three
molecules of chloroform in the unit cell, two of which are dis-
ordered over 2 positions. The disorder was modelled and both
molecules were left to freely refine to give 70% and 76% occu-
pancy for each main position.
Bacterial strains
Two Staphylococcus aureus (Gram-positive) isolates {a wild type
S. aureus strain (SH 1000) and a clinical multidrug-resistant
MRSA strain (USA 300 LAC JE2)}, and three Gram-negative
Escherichia coli isolates {MG 1655, NCTC 12241 (APEC) and ST
131 (UPEC)} and a Pseudomonas aeruginosa strain PAO1 (WT),
were used for in vitro antimicrobial studies.
MIC and MBC determination
The MIC tests were conducted by the broth micro-dilution
method in duplicate as outlined in the CLSI guidelines.42 The
MBC tests were performed in duplicate according to the stan-
dard microbiological techniques protocol.43 The bacteria were
grown in LB media incubating at 37 °C for overnight. After
washing and suspending in CAMHB, the bacteria were plated
out on Mueller–Hinton agar, grown overnight and then sus-
pended in growth medium CAMHB. Bacterial inocula were
adjusted to a turbidity equivalent to that of a 0.5 McFarland
standard and diluted to a final concentration of 4–8 × 105
cfu mL−1. Compounds tested were dissolved and serially
diluted in CAMHB in sterile 96-well flat-bottom plates to a
final volume of 100 μL in each well. An equal volume of
inocula was added to each well, making a final concentration
range of the compounds tested, including the control anti-
biotics gentamicin, of between 0.25 and 128 μg mL−1. MICs
were recorded after 16–18 h of incubation at 37 °C. Colony
counts of the inocula were performed for determination of the
MBC. After MIC results were noted, 10 μL from each well was
plated out on Mueller–Hinton agar. MBCs were recorded after
overnight incubation at 37 °C, and the concentration of com-
pounds that produced a 99.9% kill relative to the starting
inoculum was recorded as the MBC.
Cellular accumulation
The cellular accumulation of the ruthenium complexes was
measured by monitoring the luminescence of the complexes
remaining in the supernatant of the cultures after incubation
for various periods. Bacterial inocula in log phase were
adjusted to a cell concentration from 1–7 × 107 cfu mL−1. The
cell culture (24 mL) was placed in a 250 mL conical flask and
75 μL of stock solution (2.56 mg mL−1) of the ruthenium
complex was added to give a final concentration of 8 μg mL−1.
Control flasks containing 50 mL of each bacterial suspension
were set up as blank samples to obtain fluorescence cali-
bration curves for each complex. Culture flasks and control
flasks were incubated with shaking (Incu-shake TL6-5, SciQuip
Ltd, Newtown, Wem, Shropshire, UK) at 200 rpm at 37 °C for
15, 30, 60, 90 or 120 min. At each time point, 3.3 mL of
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bacterial suspension was centrifuged (5500 rpm) at 4 °C for
10 min. Supernatants (3 mL) were carefully transferred to 5 mL
tubes and the phosphorescence of the remaining ruthenium
complex was measured on a Cary Eclipse Fluorescence
Spectrophotometer with λex = 488 nm. The emission spectra
were collected from λ = 500–800 nm. Volumes (21, 39, 57,
75 and 93 μL) of a stock solution (320 μg mL−1) of each
complex were added to 3 mL aliquots of the supernatant from
each control bacterial suspension (untreated with drug) to
acquire a fluorescence-concentration linear correlation chart
for calibration.
Lipophilicity (log P) determination
The partition coefficients (log P) were measured using the
shake-flask technique. Each ruthenium complex (0.1 mM) was
dissolved in the water phase (Milli-Q water) and an equal
volume of n-octanol was added. The two phases were mutually
saturated by shaking overnight at ambient temperature and
allowed to separate on standing. The concentration of the
metal complex in each phase was determined spectrophoto-
metrically at λ = 450 nm.
DNA-binding studies
Experiments were carried out in phosphate-buffered saline
(PBS) at pH 7.4. The ratio of the UV absorbance of a solution
of CT-DNA at λ = 260 and 280 nm was greater than 1.8, thus
indicating that the CT-DNA was sufficiently free from protein.
The DNA concentration of the stock solution (2.8 × 10−3 M)
was determined by UV absorbance by using a molar absorp-
tion coefficient of 13 300 M−1 cm−1 per base pair at λ =
260 nm. Absorption titration experiments were carried out by
keeping the concentration of the ruthenium complex constant
(2 × 10−5 M) and varying the CT-DNA concentration from 0 to
fully binding. Absorbance values were recorded after each suc-
cessive addition of the solution of CT-DNA.
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